<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826928</url>
  </required_header>
  <id_info>
    <org_study_id>PO15138*</org_study_id>
    <nct_id>NCT02826928</nct_id>
  </id_info>
  <brief_title>Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors</brief_title>
  <official_title>Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      Urinary measure of 5-hydroxyindolacetic acid (5HIAA) is an important marker for the diagnosis&#xD;
      and follow-up of patients with small-intestine neuroendocrine tumors. Although this marker&#xD;
      has good specificity, its sensitivity is moderate and its dosage is constraining, since it&#xD;
      requires urine collection over 2-3 days and specific diet. Preliminary data suggested that&#xD;
      overnight 5HIAA value may be representative of 24-hour 5HIAA value, and that plasma 5HIAA&#xD;
      dosage could be a valuable alternative to urine 5HIAA dosage. The main objective of this&#xD;
      study is to compare sensitivity and specificity of overnight 5HIAA value, 24-hour 5HIAA value&#xD;
      and plasma 5HIAA value, in patients with small-intestine neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study primarily aims at comparing the sensitivity and specificity of overnight 5HIAA&#xD;
      value, 24-hour 5HIAA value and plasma 5HIAA value, in patients with small-intestine&#xD;
      neuroendocrine tumors. Secondary objectives include the correlation of 5HIAA values with&#xD;
      chromogranin A, carcinoid syndrome and tumor burden and the evaluation of the compliance to&#xD;
      the diet and its correlation with 5HIAA values.&#xD;
&#xD;
      The study group will include patients with proven neuroendocrine tumors of various stages and&#xD;
      functioning syndrome profile. A control group will be constituted with subjects having&#xD;
      irritable bowel syndrome, in which a neuroendocrine tumor is ruled out. After providing&#xD;
      informed consent, patients fitting with inclusion criteria will be included in the study.&#xD;
      Patients will have to follow a specific diet, and interrupt/avoid certain medication, during&#xD;
      the 2 days before and the 2 days during the sampling period. Whole urine samples will be&#xD;
      collected during 2 consecutive days, in 4 parts (day1, night 1, day 2, night 2). Blood&#xD;
      samples will be collected at the morning of days 2 and 3. Observance with diet and drug&#xD;
      restriction will be evaluated at the morning of day 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urine 5HIAA value</measure>
    <time_frame>24-hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)</condition>
  <arm_group>
    <arm_group_label>patients with small-intestine neuroendocrine tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control subjects with irritable bowel syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample withdrawn</intervention_name>
    <arm_group_label>control subjects with irritable bowel syndrome</arm_group_label>
    <arm_group_label>patients with small-intestine neuroendocrine tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically proven small-intestine neuroendocrine tumors, at initial diagnosis or&#xD;
             during the follow-up&#xD;
&#xD;
          -  Irritable bowel syndrome, diagnosed following Rome III criteria, who had an&#xD;
             ileo-colonoscopy and an abdominal CT-scan within the 12 last months&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  No antitumor treatment within the last three months excepted somatostatin analogs&#xD;
&#xD;
          -  Ability of understanding and approving the study protocol and of providing written&#xD;
             consent&#xD;
&#xD;
          -  Affiliation to the French Health Social System&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Small-intestine neuroendocrine tumor in remission (no detectable disease)&#xD;
&#xD;
          -  Other malignancies than small-intestine neuroendocrine tumors (excepted if in&#xD;
             remission for more than 2 years)&#xD;
&#xD;
          -  Kidney insufficiency (MDRD &lt; 60/min)&#xD;
&#xD;
          -  Urinary incontinency or inability to collect urines&#xD;
&#xD;
          -  Any antitumor treatment within the last three months excepted somatostatin analogs&#xD;
&#xD;
          -  Inability to interrupt treatments interfering with 5HIAA dosage&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients under law protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillaume Cadiot</last_name>
    <phone>326788441</phone>
    <email>gcadiot@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

